Semi-Annual Consolidated Statement Of Cash Flows

ASKA Pharmaceutical Holdings CO., Ltd. - Filing #7608022

Concept As at
2021-09-30
2021-04-01 to
2021-09-30
As at
2021-03-31
Semi-annual consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-4,139,000,000 JPY
Depreciation
1,346,000,000 JPY
Impairment losses
5,921,000,000 JPY
Interest and dividend income
-137,000,000 JPY
Interest expenses
29,000,000 JPY
Increase (decrease) in retirement benefit liability
221,000,000 JPY
Share of loss (profit) of entities accounted for using equity method
-51,000,000 JPY
Decrease (increase) in trade receivables
-1,697,000,000 JPY
Decrease (increase) in inventories
730,000,000 JPY
Increase (decrease) in trade payables
-254,000,000 JPY
Other, net
234,000,000 JPY
Subtotal
2,203,000,000 JPY
Interest and dividends received
137,000,000 JPY
Interest paid
-30,000,000 JPY
Income taxes paid
-894,000,000 JPY
Net cash provided by (used in) operating activities
1,417,000,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-262,000,000 JPY
Other, net
22,000,000 JPY
Net cash provided by (used in) investing activities
-427,000,000 JPY
Cash flows from financing activities
Repayments of long-term borrowings
-1,149,000,000 JPY
Dividends paid
-199,000,000 JPY
Net cash provided by (used in) financing activities
-1,386,000,000 JPY
Effect of exchange rate change on cash and cash equivalents
0 JPY
Net increase (decrease) in cash and cash equivalents
-396,000,000 JPY
Cash and cash equivalents
10,117,000,000 JPY
10,514,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.